Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion.

Stay informed on Israel News: All for the latest updates, and breaking news on Israeli politics, culture, Israeli sports, Health, and Tech from the Jerusalem Post ...